Navidea Biopharmaceuticals Inc. (NAVB) 1.72 $NAVB
Macrophage Therapeutics to Expand Efforts Into CNS Diseases
Business Wire - Fri Mar 20, 2:11PM CDT
Macrophage Therapeutics, Inc., a subsidiary of Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), today announced that data from an ongoing human study indicates that Navidea's Manocept(TM) technology platform has the ability to safely cross the blood brain barrier without losing its ability to deliver its payload to the intended target. Based on this data and on the advice of the Company's newly formed Scientific Advisory Board (SAB), Macrophage Therapeutics will expand the SAB to include members with specific expertise in central nervous system diseases.
NAVB: 1.72 (+0.02)
Macrophage Therapeutics, a Subsidiary of Navidea Biopharmaceuticals, Executes Securities Purchase Agreement for $2.5 Million Financing and Receives Initial Funding
Business Wire - Fri Mar 13, 2:29PM CDT
Macrophage Therapeutics, Inc., a subsidiary of Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), today announced definitive agreements have been executed for its previously announced $2.5 million round of standalone financing and the funding process is underway. The proceeds will be used for pipeline development, general working capital and recruitment of a scientific advisory board that will counsel and recommend the initial therapeutic applications of Navidea's Manocept(TM) platform technology.
NAVB: 1.72 (+0.02)
Navidea Biopharmaceuticals: Biding My Time For Alpha
Kanak Kanti De - at Seeking Alpha - Fri Mar 13, 1:36PM CDT
NAVB: 1.72 (+0.02)
Navidea Biopharmaceuticals, Inc's (NAVB) CEO Rick Gonzalez on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Mar 05, 12:39PM CST
NAVB: 1.72 (+0.02)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Thu Mar 05, 8:15AM CST
JOY: 40.41 (+1.26), EYES: 13.67 (+0.11), KR: 76.83 (+0.43), PCYC: 257.85 (-0.21), ONCY: 0.81 (-0.02), NAVB: 1.72 (+0.02), ERJ: 31.88 (+0.77), MVIS: 3.71 (-0.15), ARWR: 7.37 (-0.35), ASTI: 1.30 (-0.01), CLDN: 26.28 (-0.98), TGTX: 18.22 (-0.60), NVGN: 3.82 (-0.14), VSLR: 12.93 (-0.20), ACHN: 11.06 (-0.36), KYTH: 48.22 (+0.21), AVEO: 1.35 (-0.16), PEIX: 10.77 (+0.27), IFON: 2.30 (+0.03)
Navidea Biopharma Q4 and FY14 results
Seeking Alpha - at Seeking Alpha - Thu Mar 05, 7:25AM CST
NAVB: 1.72 (+0.02)
Navidea Biopharmaceuticals (NAVB) Q4 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Thu Mar 05, 7:25AM CST
NAVB: 1.72 (+0.02)
Navidea Biopharm EPS in-line, beats on revenue
Seeking Alpha - at Seeking Alpha - Thu Mar 05, 6:33AM CST
NAVB: 1.72 (+0.02)
Navidea, Norgine partner on Lymphoseek
Seeking Alpha - at Seeking Alpha - Thu Mar 05, 6:22AM CST
NAVB: 1.72 (+0.02)
Notable earnings before Thursday’s open
Seeking Alpha - at Seeking Alpha - Wed Mar 04, 4:30PM CST
JOY: 40.41 (+1.26), SFE: 17.94 (-0.06), KR: 76.83 (+0.43), NAVB: 1.72 (+0.02), BKCC: 9.17 (-0.02), BRLI: 34.10 (-0.41), BTE: 14.89 (+0.68), CECE: 12.06 (-0.05), CTCM: 3.89 (+0.18), CVGW: 52.85 (+0.61), CNQ: 29.60 (+0.86), MEI: 45.57 (+0.23), GTN: 14.42 (-0.04), CSIQ: 34.88 (+0.18), EXK: 2.06 (unch), CIEN: 20.63 (+0.16), AXAS: 2.91 (-0.21), AMRC: 7.28 (+0.37), DATE: 5.10 (unch), COST: 152.59 (+1.28), PRFT: 20.72 (-0.10), ACRE: 11.55 (+0.22)
Expert Briefing on Biotech Stocks - Lexicon Pharma, Sunesis Pharma, Navidea Biopharma, Tekmira Pharma, and Intrexon
PR Newswire - Thu Feb 19, 7:35AM CST
Editor Note: For more information about this release, please scroll to bottom.
NAVB: 1.72 (+0.02), LXRX: 1.10 (-0.04), XON: 46.11 (-1.26), TKMR: 19.48 (-1.01), SNSS: 2.60 (-0.04)
Lymphoseek(R) Data Presented in European Medical Conference Reinforces Clinical Value in Head & Neck Cancer of the Oral Cavity
Business Wire - Wed Feb 18, 9:53AM CST
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) today reported that a Lymphoseek(R) (technetium Tc 99m tilmanocept) injection presentation at the International Conference on Innovative Approaches in Head and Neck Oncology contributes to a growing body of data reinforcing the clinical value of Lymphoseek, specifically for guiding sentinel lymph node biopsy in head and neck cancer patients with squamous cell carcinoma of the oral cavity. The data, presented by Remco de Bree, M.D., Ph.D. head and neck surgeon from the VU University Medical Center, The Netherlands, included the following:
NAVB: 1.72 (+0.02)
Lymphoseek(R) Results from Phase 3 Clinical Trial in Oral Cavity Cancer of the Head and Neck Published in Annals of Surgical Oncology
Business Wire - Tue Feb 17, 6:30AM CST
Navidea Biopharmaceuticals, Inc. (NYSE MKT:NAVB), today announced the peer-reviewed publication of results from a Phase 3 clinical trial of Lymphoseek(R) (technetium 99m tilmanocept) injection in patients with certain head and neck cancer (squamous cell carcinoma of the oral cavity, NEO3-06; NCT00911326) in the journal Annals of Surgical Oncology. The trial assessed the performance of Lymphoseek-guided sentinel node biopsy against the standard of care, nodal pathology, in planned elective neck dissection (END). Results demonstrated that Lymphoseek met the primary efficacy endpoint of accurately identifying sentinel lymph nodes (SLNs) in subjects with node-negative squamous cell carcinoma of the oral cavity, as compared to the removal of all lymph nodes during multiple level nodal dissection surgery of the head and neck. Pathology assessment of lymph nodes from the multiple level nodal dissection surgery is considered the "gold standard" to determine the presence and extent of cancer spread.
NAVB: 1.72 (+0.02)
Achillion Soars on 6 Week HCV Cure When Used with Gilead's Sofosbuvir - Stocks in the News
Zacks Research Staff - Zacks Investment Research - Mon Feb 09, 2:38PM CST
Achillion shares are up nearly double digits today thanks to promising results for its ACH-3102 when used in combination with Gilead Sciences' (GILD) sofosbuvir.
NAVB: 1.72 (+0.02), AUPH: 5.25 (+0.01), GILD: 102.29 (+0.85), ACHN: 11.06 (-0.36)
Navidea reports preliminary 2014 revenue
Seeking Alpha - at Seeking Alpha - Mon Feb 09, 7:07AM CST
NAVB: 1.72 (+0.02)
Navidea Reports Preliminary 2014 Revenue; Provides Update on New Commercial Strategy
Business Wire - Mon Feb 09, 6:30AM CST
Navidea Biopharmaceuticals, Inc. (NYSE MKT:NAVB) today reports preliminary, unaudited total revenue of $6.3 million for the year ended December 31, 2014, including total product revenue from Lymphoseek(R) (technetium Tc 99m tilmanocept) injection of $4.2 million. For the three months ended December 31, 2014, Navidea reports preliminary, unaudited total revenue of $2.2 million, including total product revenue from Lymphoseek of $1.5 million. Total revenue includes product revenue from sales of Lymphoseek to the Company's distribution partner, grant revenue and revenue generated from business development activities; however, it should be noted product revenue recognized by Navidea represents only a portion of the total brand revenue generated by the distribution partner on sales of Lymphoseek to end customers. Navidea's gross profit is expected to be $4.7 million for the year ended December 31, 2014 and $1.9 million for the three months ended December 31, 2014.
NAVB: 1.72 (+0.02)
Navidea's Macrophage Therapeutics Gets A $2.5 Million Vote Of Confidence
Basileus - at Seeking Alpha - Tue Feb 03, 1:57PM CST
NAVB: 1.72 (+0.02)
Navidea to report preliminary results next Monday
Seeking Alpha - at Seeking Alpha - Mon Feb 02, 3:06PM CST
NAVB: 1.72 (+0.02)
Navidea to Report Preliminary 2014 Revenue and Present at BIO CEO & Investor Conference February 9
Business Wire - Mon Feb 02, 2:17PM CST
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), today announced that the Company will report preliminary fourth quarter and full year 2014 revenues and provide a business update before market open on Monday, February 9, 2015. In addition, Rick Gonzalez, Chief Executive Officer, will present at the 17th Annual BIO CEO and Investor Conference at 10:00 am EST on February 9, 2015.
NAVB: 1.72 (+0.02)
Macrophage Therapeutics to Expand Efforts Into CNS Diseases
Business Wire - Fri Mar 20, 2:11PM CDT
Macrophage Therapeutics, Inc., a subsidiary of Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), today announced that data from an ongoing human study indicates that Navidea's Manocept(TM) technology platform has the ability to safely cross the blood brain barrier without losing its ability to deliver its payload to the intended target. Based on this data and on the advice of the Company's newly formed Scientific Advisory Board (SAB), Macrophage Therapeutics will expand the SAB to include members with specific expertise in central nervous system diseases.
NAVB: 1.72 (+0.02)
Macrophage Therapeutics, a Subsidiary of Navidea Biopharmaceuticals, Executes Securities Purchase Agreement for $2.5 Million Financing and Receives Initial Funding
Business Wire - Fri Mar 13, 2:29PM CDT
Macrophage Therapeutics, Inc., a subsidiary of Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), today announced definitive agreements have been executed for its previously announced $2.5 million round of standalone financing and the funding process is underway. The proceeds will be used for pipeline development, general working capital and recruitment of a scientific advisory board that will counsel and recommend the initial therapeutic applications of Navidea's Manocept(TM) platform technology.
NAVB: 1.72 (+0.02)
Navidea Biopharmaceuticals: Biding My Time For Alpha
Kanak Kanti De - at Seeking Alpha - Fri Mar 13, 1:36PM CDT
NAVB: 1.72 (+0.02)
Navidea Biopharmaceuticals, Inc's (NAVB) CEO Rick Gonzalez on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Mar 05, 12:39PM CST
NAVB: 1.72 (+0.02)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Thu Mar 05, 8:15AM CST
JOY: 40.41 (+1.26), EYES: 13.67 (+0.11), KR: 76.83 (+0.43), PCYC: 257.85 (-0.21), ONCY: 0.81 (-0.02), NAVB: 1.72 (+0.02), ERJ: 31.88 (+0.77), MVIS: 3.71 (-0.15), ARWR: 7.37 (-0.35), ASTI: 1.30 (-0.01), CLDN: 26.28 (-0.98), TGTX: 18.22 (-0.60), NVGN: 3.82 (-0.14), VSLR: 12.93 (-0.20), ACHN: 11.06 (-0.36), KYTH: 48.22 (+0.21), AVEO: 1.35 (-0.16), PEIX: 10.77 (+0.27), IFON: 2.30 (+0.03)
Navidea Biopharma Q4 and FY14 results
Seeking Alpha - at Seeking Alpha - Thu Mar 05, 7:25AM CST
NAVB: 1.72 (+0.02)
Navidea Biopharmaceuticals (NAVB) Q4 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Thu Mar 05, 7:25AM CST
NAVB: 1.72 (+0.02)
Navidea Biopharm EPS in-line, beats on revenue
Seeking Alpha - at Seeking Alpha - Thu Mar 05, 6:33AM CST
NAVB: 1.72 (+0.02)
Navidea, Norgine partner on Lymphoseek
Seeking Alpha - at Seeking Alpha - Thu Mar 05, 6:22AM CST
NAVB: 1.72 (+0.02)
Notable earnings before Thursday’s open
Seeking Alpha - at Seeking Alpha - Wed Mar 04, 4:30PM CST
JOY: 40.41 (+1.26), SFE: 17.94 (-0.06), KR: 76.83 (+0.43), NAVB: 1.72 (+0.02), BKCC: 9.17 (-0.02), BRLI: 34.10 (-0.41), BTE: 14.89 (+0.68), CECE: 12.06 (-0.05), CTCM: 3.89 (+0.18), CVGW: 52.85 (+0.61), CNQ: 29.60 (+0.86), MEI: 45.57 (+0.23), GTN: 14.42 (-0.04), CSIQ: 34.88 (+0.18), EXK: 2.06 (unch), CIEN: 20.63 (+0.16), AXAS: 2.91 (-0.21), AMRC: 7.28 (+0.37), DATE: 5.10 (unch), COST: 152.59 (+1.28), PRFT: 20.72 (-0.10), ACRE: 11.55 (+0.22)
Expert Briefing on Biotech Stocks - Lexicon Pharma, Sunesis Pharma, Navidea Biopharma, Tekmira Pharma, and Intrexon
PR Newswire - Thu Feb 19, 7:35AM CST
Editor Note: For more information about this release, please scroll to bottom.
NAVB: 1.72 (+0.02), LXRX: 1.10 (-0.04), XON: 46.11 (-1.26), TKMR: 19.48 (-1.01), SNSS: 2.60 (-0.04)
Lymphoseek(R) Data Presented in European Medical Conference Reinforces Clinical Value in Head & Neck Cancer of the Oral Cavity
Business Wire - Wed Feb 18, 9:53AM CST
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) today reported that a Lymphoseek(R) (technetium Tc 99m tilmanocept) injection presentation at the International Conference on Innovative Approaches in Head and Neck Oncology contributes to a growing body of data reinforcing the clinical value of Lymphoseek, specifically for guiding sentinel lymph node biopsy in head and neck cancer patients with squamous cell carcinoma of the oral cavity. The data, presented by Remco de Bree, M.D., Ph.D. head and neck surgeon from the VU University Medical Center, The Netherlands, included the following:
NAVB: 1.72 (+0.02)
Lymphoseek(R) Results from Phase 3 Clinical Trial in Oral Cavity Cancer of the Head and Neck Published in Annals of Surgical Oncology
Business Wire - Tue Feb 17, 6:30AM CST
Navidea Biopharmaceuticals, Inc. (NYSE MKT:NAVB), today announced the peer-reviewed publication of results from a Phase 3 clinical trial of Lymphoseek(R) (technetium 99m tilmanocept) injection in patients with certain head and neck cancer (squamous cell carcinoma of the oral cavity, NEO3-06; NCT00911326) in the journal Annals of Surgical Oncology. The trial assessed the performance of Lymphoseek-guided sentinel node biopsy against the standard of care, nodal pathology, in planned elective neck dissection (END). Results demonstrated that Lymphoseek met the primary efficacy endpoint of accurately identifying sentinel lymph nodes (SLNs) in subjects with node-negative squamous cell carcinoma of the oral cavity, as compared to the removal of all lymph nodes during multiple level nodal dissection surgery of the head and neck. Pathology assessment of lymph nodes from the multiple level nodal dissection surgery is considered the "gold standard" to determine the presence and extent of cancer spread.
NAVB: 1.72 (+0.02)
Achillion Soars on 6 Week HCV Cure When Used with Gilead's Sofosbuvir - Stocks in the News
Zacks Research Staff - Zacks Investment Research - Mon Feb 09, 2:38PM CST
Achillion shares are up nearly double digits today thanks to promising results for its ACH-3102 when used in combination with Gilead Sciences' (GILD) sofosbuvir.
NAVB: 1.72 (+0.02), AUPH: 5.25 (+0.01), GILD: 102.29 (+0.85), ACHN: 11.06 (-0.36)
Navidea reports preliminary 2014 revenue
Seeking Alpha - at Seeking Alpha - Mon Feb 09, 7:07AM CST
NAVB: 1.72 (+0.02)
Navidea Reports Preliminary 2014 Revenue; Provides Update on New Commercial Strategy
Business Wire - Mon Feb 09, 6:30AM CST
Navidea Biopharmaceuticals, Inc. (NYSE MKT:NAVB) today reports preliminary, unaudited total revenue of $6.3 million for the year ended December 31, 2014, including total product revenue from Lymphoseek(R) (technetium Tc 99m tilmanocept) injection of $4.2 million. For the three months ended December 31, 2014, Navidea reports preliminary, unaudited total revenue of $2.2 million, including total product revenue from Lymphoseek of $1.5 million. Total revenue includes product revenue from sales of Lymphoseek to the Company's distribution partner, grant revenue and revenue generated from business development activities; however, it should be noted product revenue recognized by Navidea represents only a portion of the total brand revenue generated by the distribution partner on sales of Lymphoseek to end customers. Navidea's gross profit is expected to be $4.7 million for the year ended December 31, 2014 and $1.9 million for the three months ended December 31, 2014.
NAVB: 1.72 (+0.02)
Navidea's Macrophage Therapeutics Gets A $2.5 Million Vote Of Confidence
Basileus - at Seeking Alpha - Tue Feb 03, 1:57PM CST
NAVB: 1.72 (+0.02)
Navidea to report preliminary results next Monday
Seeking Alpha - at Seeking Alpha - Mon Feb 02, 3:06PM CST
NAVB: 1.72 (+0.02)
Navidea to Report Preliminary 2014 Revenue and Present at BIO CEO & Investor Conference February 9
Business Wire - Mon Feb 02, 2:17PM CST
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), today announced that the Company will report preliminary fourth quarter and full year 2014 revenues and provide a business update before market open on Monday, February 9, 2015. In addition, Rick Gonzalez, Chief Executive Officer, will present at the 17th Annual BIO CEO and Investor Conference at 10:00 am EST on February 9, 2015.
NAVB: 1.72 (+0.02)
